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Abstract
(+)-Boldine, an aporphine alkaloid, has been reported to be biologically active at various
receptors: α-adrenergic and dopamine receptors, but very few Structure Activity Relationship
(SAR) studies on (+)-boldine with respect to its activity on the serotonin receptors (5-HT) have
been conducted. To this purpose, a library of novel analogs was synthesized from commercially
available (+)-boldine via Mitsunobu reaction to assess the effect of bisbenzylation at the C2 and
C9 positions on the affinity and selectivity at serotonin receptors.
As compared to (+)-boldine, the bisbenzylated analogues had diminished affinity at the
5HT1A, 5HT1D, 5HT2B, 5HT6, and 5HT7 receptors. Moderate improvement in the affinity was
observed at 5HT2A and 5HT2C receptors. Thus, bisbenzylation of (+)-boldine at the C2 and C9
positions increased the selectivity and affinity to the 5HT2A, 5HT2C receptors over the 5HT1A,
5HT1D, 5HT2B, 5HT6, and 5HT7 receptors.
Our findings will be useful in the future design of high affinity 5HT2A and 5HT2C ligands
based on the C2 and C9 benzylation of (+)-boldine’s aporphine core structure.
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Chapter 1: Introduction
1.1.1 Alkaloids
Natural products have played crucial roles in treating and preventing a plethora of human
diseases. Medicines have come from various sources: plants, microorganisms, marine organisms
among others. Licorice and myrrh – the earliest examples of natural products with medical
relevance derived from plant sources, dates to 2600BC in Mesopotamia. Currently, the number
of natural products with medical relevance is immense and increasing exponentially.1
Alkaloids are a class of natural products which were discovered via systemic studies since
the beginning of the 19th century. In alkaloid plants, the primary function of the alkaloids
predominantly involves protection from grazing animals and herbivorous insects.2 The first
alkaloid synthesized and its structure elucidated was Coniine (Fig. 1). In the 1940’s the number
of alkaloids was roughly around 800. In the last 70 years, this figure has increased exponentially
to 12000 due to improvement in separation techniques and better equipment.2 Most alkaloids are
basic in nature and also contain at least one nitrogen in a heterocyclic ring.3 Many of the
alkaloids have potent biological activity and as a result these are used as pharmaceuticals,
stimulants and poison.4

Fig. 1: Coniine
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1.1.2 Aporphines: Occurrence, Structure and Biological Activity
Aporphines are one of the largest groups of the isoquinoline class of alkaloids. Currently,
more than 500 aporphines structures have been reported. Aporphines have been classified into
several subfamilies namely: aporphines, proaporphines, secoaporphines, oxoaporphines,
dehydroaporphines, 7-hydroxyaporphines, aporphine dimers, and aristolactams.5,6 (Fig. 2)
Aporphines are usually obtained from plants including members of the Annonaceae, Lauraceae,
Monimiaceae, Menispermaceae, Hernandiaceae and Ranunculaceae families among others.2

Fig. 2: Members and subfamilies of aporphines
Aporphine alkaloids have a tetracyclic skeleton which includes an isoquinoline core and
one stereogenic center at C-6a.7 (Fig. 3)
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Fig. 3: Aporphine skeleton and carbon numbering scheme
Aporphine alkaloids and derivatives have been of great importance as these have
antioxidative, malarial, viral and cytoprotective activity. Aporphines act on various receptors in
the CNS both in vitro and in vivo as antagonists or agonists at the adrenergic, dopamine and
serotonin receptors.6 Research has also suggested that some of the aporphines can be used are
potent anti-cancer agents. Aporphines continue to be of great importance in the field of
medicinal chemistry as they are very promising for the discovery of new ligands with high
potency and selectivity for various CNS receptor subtypes.6
1.1.3 G-Protein Coupled Receptors (GPCR): Structure and Signaling
G-Protein coupled receptors (GPCRs) form the largest superfamily of receptors in the
cell. GPCRs play pivotal role in regulating physiological processes such as sensory perception,
immune defense, cell communication, chemotaxis and neurotransmission. Not surprisingly, 50%
of the drugs in the market target/modulates the effects of GPCRs.8
GPCRs are integral proteins characterized by a 7TM (Transmembrane) helix because they
contain seven transmembrane alpha-helices. These 7TM loops have hydrophobic domains
tethered to the cell membrane, a carboxyl terminus, which is present on the cytosolic side of the
cell and an amino terminus which is present on the extracellular side of the cell. There are three
loops present on the outside of the cell that together form the ligand binding site. Three loops are
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also present on the cytoplasmic side of the plasma membrane that provide binding site for
intracellular signaling proteins.9 (Fig. 4)

https://upload.wikimedia.org/wikipedia/commons/6/66/GPCR.png

http://2012.igem.org/Team:Chalmers-Gothenburg/Theory
Fig. 4: GPCR (G-Protein Coupled Receptor) structure
GPCRs are classified into 6 subfamilies (A-F) based on sequence homology. Alternatively,
GPCRs are also categorized into numerical subfamilies (1-5). Class A/1 contains Rhodopsin like
family, Class B/2 includes secretin like family, Class C/3 contains metabotropic glutamate and
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pheromone family, Class D/4 encapsulates fungal pheromones, Class E includes cAMP receptor
family and Class F/5 includes the frizzled/smoothened family. Class A/1 is the largest and
includes the cationic neurotransmitters and cannabinoid and EDG (Endothelial Differentiation
Gene) receptors which have lipid derived endogenous ligands. Additionally, serotonin (5-HT),
dopamine and adrenergic receptors are also part of the Class A/1 Rhodopsin like family.10
Members of the GPCRs are activated/deactivated by a wide range of molecules/ligands.
Activated/deactivated GPCRs catalyze an exchange of Guanosine triphosphate (GTP) for
Guanosine diphosphate (GDP) bound to the inactive G-protein α subunit, resulting in
conformation change and dissociation of the complex. Consequently, separation of the G-protein
α subunits from the β, γ is followed by a signaling cascade that passes information to the inside
of the cell via interaction with the G-protein with the receptor.10 (Fig. 4).
In mammals, G protein α subunits are encoded by a multigene family containing at least
16 different subunit genes. The α subunit genes have been grouped into four classes: Gs, Gi, Gq,
and G12, based on sequence homology, gene structure, and regulation of specific effectors.11 Gs
subunit stimulates/activates the cAMP-dependent pathway by activating adenylyl cyclase. The
signal can be further magnified by the interaction of adenylyl cyclase with a host of proteins. G i
subunit inhibits/deactivates the cAMP-dependent pathway by deactivating adenylyl cyclase. Gq
proteins activate phospholipase C (PLC), which participates in a variety of cellular signaling
pathways.12
1.1.4 Overview pertinent receptors - Central Nervous System
There are variety of substances in the Central Nervous System that serve as
neurotransmitters (NT) and neuromodulators. Some of the substances include amino acids and
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amino acid derivatives, amines, peptides and purine derivatives. Glutamate, GABA, Glycine are
few amino acids which act as NTs. Amine NTs include norepinephrine, epinephrine, dopamine,
serotonin and histamine.13 Substance P and β-endorphin are peptides involved in the
neurotransmission.14 Purines derivatives include ATP and Adenosine. 15
Aporphines are useful ligands for central nervous system receptors and possess high
affinity for a number of dopamine receptors (D1/D2), serotonin (5-HT) and α-adrenergic
receptors. Aporphines are known to be endowed with both agonist and antagonist activity at
neuroreceptor sites.16 As such, a brief review of these receptors and subtypes merits discussion.
Dopamine (Fig. 5) is involved in a number of processes including motor control,
autonomic function and motivation among others. Abnormal levels of dopamine are involved in
a number of debilitating diseases including Schizophrenia, Parkinson’s disease, attention deficit
hyperactivity disorder (ADHD), drug addiction and psychosis.17 Dopamine is synthesized in
specific neurons, striatum and the limbic system and is released in dopaminergic synaptic clefts
to elicit physiological effects after binding at dopamine receptors.24 Dopamine receptors in the
CNS are grouped in two large families- D1, D2 based on c-DNA studies, synaptic action and
signaling mechanism of the receptors. The D1 family consists of D1 and D5 receptors. Both of the
receptors are coupled to Gαs which is involved in increasing cAMP levels and thus the
excitability of the cell. D1 receptors is the most abundant subtype in the mammalian forebrain
and D5 receptors are relatively sparse and less widely distributed compared to D1 receptors.
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Doxanthrine and Dihydrexidine are selective ligands of D1 and D5 respectively.18 (Fig. 6)
The D2 class includes D2, D3, D4 receptors. The D2 receptors are coupled to Gαi, which
leads to decreased cAMP levels. Subsequently, the excitability of cells is regulated.8 D2 receptor
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is second behind D1 in abundance in the mammalian forebrain. Some of the drugs that decrease
symptoms of Parkinson’s disease target D2 receptors.17 Aripiprazole, Nafadotride and ABT 724
Trihydrochloride are some examples of selective ligands of the D2, D3, D4 families respectively.
19,20,21

(Fig. 7)

Fig. 5: Dopamine – Native ligand of Dopamine receptors

Fig. 6: Selective D1, D5 Ligands
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Fig. 7: Selective D2, D3, D4 Ligands
Adrenergic receptors are also a class of GPCRs that are target of ligands of the
catecholamine family. Adrenergic receptors are involved in circulation and the fight-flight
response. There are two main groups of adrenergic receptors α and β. α adrenergic receptors are
divided into two groups: α1 and α2. α1 subtypes include α1A, α1B and α1D. α2 adrenoreceptors are
classified into α2A, α2B and α2C. α1 adrenoreceptors are found in the CNS and Peripheral Nervous
System(PNS). In the CNS they are located post synaptically and are involved in modulating
excitation.22,23 In the PNS, α1 receptors are located on vascular and smooth muscle and are
involved in contraction. α1 receptors are linked to Gq GPCRs and α2 receptors are linked to Gi
GPCRs. α2 adrenoreceptors are located on pre and post synaptic neurons and they mediate
inhibitory role in the CNS and PNS. Phenylephrine is a selective agonist for α1-receptor.24 (Fig.
8) β-adrenoreceptors are divided into subtypes: β1, β2, β3 and β4. The β1-adrenoreceptor is
predominant in the striatum and heart and β2 is predominant in vascular, uterine and smooth
muscle in the airway. β1 is coupled to Gs GPCRs and is involved in stimulatory responses.
However, other β-receptors can be either excitatory or inhibitory or a combination of both.
Clenbuterol is a selective agonist of β2 adrenoreceptor.25 (Fig. 8)

22,23
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Fig. 8: Selective α1 and β2-receptor ligands
1.1.4.1 Serotonin Receptors: Structure and function and Clinical Implications
Serotonin (5-hydroxytryptamine, 5-HT) (Fig. 9) is another NT which is involved in wide
array of functions including cognition and behavioral functions. In the brain serotonin is
produced in the axon terminals and it diffuses out into the synaptic cleft to activate postsynaptic
receptors. Any alteration in its neurochemistry is associated with a plethora of neuropsychiatric
disorders.26

The serotonin family of receptors is larger than any other family of GPCRs: 13

distinct genes encode for each of the Serotonin GPCRs of the 7TM class. Studies on
pharmacology, amino acid sequence similarity and signaling mechanisms suggest that there are
at least 14 different receptor subtypes of serotonin receptors, which are divided into seven
families - 5HT1 to 5HT7.

27,28

All of the serotonin receptors are members of the type A/1

rhodopsin G-Protein Coupled Receptors (GPCRs) as described earlier, with one exception – the
5HT3 receptor, which is a ligand gated ion channel. Serotonin agonists and antagonists for
different 5-HT subfamilies are also useful drug targets for the treatment of numerous diseases
and many of these ligands are readily available for clinical use. 27, 28
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Fig. 9: Serotonin – Native ligand of Serotonin Receptors
The 5-HT1 family is subdivided into five subfamilies: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and
5-HT1F. 5-HT1A receptors were the first serotonin 5-HT1 receptors to be cloned and
characterized. Like all other 5-HT1 type receptors, the 5-HT1A receptor is characterized by its
high affinity to serotonin. 5HT1A receptors are distributed pre and post synaptically within the
brain.27,28 The activation of the 5-HT1A receptors lead to neuronal hyperpolarization which in
turn reduces firing rate of neurons. The presynaptic receptors are located in the raphe nuclei and
are coupled to G-αi/o receptors. Postsynaptic 5-HT1A receptors are expressed densely in the
limbic areas of the brain like the hippocampus and the septum.27, 28 Preclinical studies show that
the 5-HT1A receptors play important roles in anxiety and depression. Additionally, the 5-HT1A
receptors are also linked to schizophrenia and symptoms related to Parkinson’s, neuroprotection
and addiction to psychostimulants like amphetamine and cocaine. Agonists of these receptors
have shown antidepressant properties while the antagonists are linked to weight reduction.
The most known 5-HT1A available compound is the agonist Buspirone.29 (Fig. 10)

27, 28
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Fig. 10: Selective 5-HT1A ligand
5-HT1B receptors are widely distributed throughout the CNS and its function varies
depending on its location. Within the brain neurons, 5-HT1B receptors are presynaptic and are
localized on axon terminals. Clinical studies indicate that the 5-HT1B receptors are involved in
regulation of aggression, learning and memory processes and premature ejaculation.27,28 5-HT1B
receptors are also thought to be involved in depression.11 Ergotamine is a selective agonist of the
5-HT1B receptor.30 (Fig. 11)

Fig. 11: Selective 5-HT1B ligand
5-HT1D receptors are located mostly within the basal ganglia and substantia nigra of the
brain. 5-HT1D

receptors are linked with migraines and coronary vasoconstriction.27,28

Sumatriptan is a well-known 5-HT1D agonist which is used to treat migraines.31 (Fig. 12)
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Fig. 12: Selective 5-HT1D ligand
5-HT1E receptors are present mostly in the cortical layers II-VI and the hippocampus.
Current understanding of 5-HT1E receptors function is poor, because there are no ligands specific
for the 5-HT1E receptors. However, 5-HT1E receptors may play important roles in cognition and
memory processes. 27,28
5-HT1F receptors are distributed widely in the brain and the spinal cord. 5-HT1F receptors
are involved in acute migraines which are not accompanied by coronary vasoconstriction.

27,28

LY334370 is an agonist for 5-HT1F receptors.32 (Fig. 13)

Fig 13: Selective 5-HT1F ligand
5-HT2 receptor family is subdivided into three subfamilies: 5-HT2A, 5-HT2B and 5-HT2C. 5HT2 receptor family is coupled to G-αq GPCRs. 5-HT2 receptor family use protein kinase C
(PKC) and calcium as second messenger system.27,28 (Fig. 14)
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http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/S/Second_messengers.html
Fig 14: PKC, Calcium second messenger system
5-HT2A receptors are distributed at varying densities in the brain; the highest density is in
the neocortex. 5-HT2A receptors are involved in closing/opening of channels in the brain,
synaptic plasticity, analgesia in the spine and modulates various cardiovascular functions.
Interestingly, 5-HT2A receptors are also key sites for hallucinogenic action. Psilocybin is an
example of an agonist which has hallucinogenic properties.27,28 Ketanserin is an antagonist which
prevents psilocybin from binding to the 5-HT2A receptor.33 (Fig. 15)

Fig. 15: Selective 5-HT2A ligand
5-HT2B receptors are mostly expressed in the kidneys, livers lungs. However, these are
only weakly expressed in the brain. 5-HT2B receptor is the only 5-HT receptor that is necessary
for viability. 5-HT2B receptors are linked to vulnerability to drug abuse, accurate functioning of
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auditory system and proper formation of key structures in the heart and brain during
development. Additionally, 5-HT2B receptors activation in the adult heart can at times lead to
heart disease or fatality. Thus, antagonists of 5-HT2B receptors in the heart can be useful in
treating cardiac hypertrophy.27,28 RS-127445 is a selective antagonist of the 5-HT2B receptor.34
(Fig. 16)

Fig. 16: Selective 5-HT2B ligand
5-HT2C receptors are mostly expressed in the choroid plexus region of the brain and it may
help in regulating ion exchange between the brain and the CSF. 5-HT2C receptors also modulate
dopaminergic function and might be involved in schizophrenia, depression, anxiety, appetite
control and cardiovascular function.27,28 Fenfluramine is a selective agonist of 5-HT2C receptor.35
(Fig. 17)

Fig. 17: Selective 5-HT2C ligand
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5-HT3 receptors are mostly expressed in the peripheral and central nervous system at
varying degrees. 5-HT3 receptors don’t belong to the GPCR class of receptors and are nonselective cation (Na+/K+) ion channel receptors. These are closely related to the cysteine-loop
ligand gated superfamily which includes Acetocholine nicotinic receptor, glycine and GABAA
receptor. 27,28
5-HT4 receptors are expressed both centrally and peripherally in the nervous system. 5-HT4
receptors have low homology sequence to other 5-HT receptors and are involved in learning
(long term potentiation), synaptic plasticity, and relaxation of the colon.27,28 Cisapride is an
agonist of 5-HT4 receptors.36 (Fig. 18)

Fig. 18: Selective 5-HT4 Ligand
5-HT5 receptors have two isoforms: 5-HT5A and 5-HT5B. Currently, only 5-HT5A is thought
to be present in humans. 5-HT5A receptors are broadly expressed in the CNS. Not much is known
about the function as no selective ligand has been found, although 5-HT5A receptors are
implicated in control of circadian rhythm.27,28
5-HT6 receptors are predominantly expressed in the CNS. However, not much is known
about the function of 5-HT6 receptors as very few selective agonists have been found.
Nevertheless, this receptor may have potential therapeutic activity for anxiety, depression,
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schizophrenia, epilepsy, obesity.27,28

EMD-386088 is a potent and selective 5-HT6 agonist.37

(Fig. 19)

Fig. 19: 5-HT6 Ligand
5-HT7 receptors comprise of 5-HT7A, 5-HT7B, 5-HT7C and 5-HT7D receptors. 5-HT7C, receptors
are found only in rats. 5-HT7 receptors are mainly found in the CNS. These receptors are
believed to important in regulating sleep, hypertension, overall mood of an individual and
regulating body temperature.27-28 Fluphenazine is a 5-HT7 antagonist
schizophrenia.38 (Fig 20)

Fig. 20: Selective 5-HT7 ligand

which is used to treat
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Table 1: Few examples of selective ligands used as therapeutics (NA- Not Applicable)
Receptor

Functional Activity

Therapeutic Use

Ligand

D1
D2
D3
D4
D5
α1
β2
5-HT1A
5-HT1B
5-HT1D
5-HT1F
5-HT2A
5-HT2B
5-HT2C
5-HT4

Agonist
Partial Agonist
Antagonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Agonist
Antagonist
Agonist
Agonist

Doxanthrine
Aripiprazole
Nafadotride
ABT 724 trihyrdochloride
Dihydrexidine
Phenylephrine
Clenebuterol
Buspirone
Ergotamine
Sumatriptan
LY334370
Ketanserin
RS-127445
Fenfluramine
Cisapride

5-HT6
5-HT7

Agonist
Antagonist

Parkinsons
Antipsychotic
Antidepressant
Vasodilator
Schizophrenia
Decongestant
Broncodilator
Antianxiety
Vasoconstrictor
Migraine
Migraine
Antihypertensive
NA
Anorectic agent
Gastroprokinetic
agent
NA
Antipsychotic

EMD- 386088
Fluphenazine

1.1.5 Structure Activity Relationships (SAR) studies of Aporphines at CNS
A plethora of studies can be found on the SAR of the aporphines because aporphines
exhibit biological activity at various neuroreceptor sites.16 Various alkaloids containing the
aporphine skeleton were found to have moderate activity towards dopamine receptors.17 Since
many of the aporphine alkaloids have nonselective and weak/moderate activity, optimization
studies may be done to enhance pharmacological activities as well as enhance understanding of
ligand binding to receptors. As a result of these studies, new compounds can be identified which
are selective towards a particular receptor. Furthermore, this approach can potentially lead to
development of new and useful pharmacological tools and therapeutics.
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A few studied aporphines are (S)-boldine, (R)-apomorphine and (S)-bulbocapnine. SAR
studies on a series of substituted aporphines indicate that substitutions on ring A at C1 or C2
positions wherein hydroxy or methoxy groups in aporphine scaffold are replaced, increased
affinity at dopamine receptors whereas, substituents on ring D at C9 position tended to have the
opposite effect on dopamine receptors.40 (Fig. 21,22) The stereochemistry of the chiral center at
C-6a was also an important factor which determines whether a ligand is an antagonist or an
agonist. (R)-analogs were found to display agonist activity whereas the (S) molecules were found
to display weak agonist, partial agonist and antagonist activity.41 It is known that (R)apomorphine is a potent dopamine D2 receptor agonist. Both (R) and (S) apomorphine were
screened on various receptors and it was found that (S)-apomorphine binds to dopamine and αadrenoreceptors, while (R) form was active at α2-adrenoreceptors.42 Furthermore, compounds
that contained an electropositive or electronegative C2 substituent were found to display high D2
binding potency and good D2/D1 selectivity. Tolerance to variable C2 substituents might be
indicative of a lipophilic cleft that could potentially interact with the substituents at C-2
position.43 Meta –OH substituent on ring A at C-2 position seemed to be of great importance for
D2 receptor affinity as it may be involved in hydrogen bonding with the hydroxyl group and
peptides on the surface of D2 proteins.44

Fig 21: C1, C2 substituted apomorphine
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Fig 22: C9 substituted apomorphine
In additional studies, it was revealed that small structural changes to the aporphine core
significantly affects the receptor binding profile in both in vivo and in vitro systems. For
example: structural modification of the non-selective agonist aporphine (R)-apomorphine at C11
was done to study the SAR at D1, D2 and 5-HT1A receptors. It was discovered that the catechol
functionality is not required for binding the DA receptors with high affinity. Hydrogen bond at
C11 position was deemed as non-essential for high affinity binding to D1/D2 and 5-HT1A
receptors.45 An increase in affinity and selectivity for 5-HT1A was observed when the size of the
N-substituent was limited to methyl or hydrogen.46
SAR studies on predicentrine (Fig. 23) show that iodination, bromination at C3 position
on ring A increased selectivity potency compared to the parent compound at D1 receptor.47
Binding studies on C1-C11 bridged aporphines analogs show that these compounds have good
affinity at 5-HT receptors: 5-HT1A and 5-HT7 but have variable interaction with DA receptors.6,48
(Fig. 25)

Claudi and colleagues synthesized and reported a series of C12-C13 bridged

aporphines which had similar profiles as the C1-C11 bridged aporphines.49 (Fig. 26) SAR on the
N-6 against DA receptors showed that the replacement of N-methyl with ethyl, propyl gave more
potent agonists at D2 receptor.49,50
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Fig 23: Predicentrine, a DA ligand

Fig 24: Halogenated predicentrine analogue active at D1 receptors

Fig 25: C1, C11 bridged aporphine active at 5-HT receptors

Fig 26: C12, C13 Bridged aporphine active at 5-HT receptors
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SAR studies have been really useful tools in development of potent dopaminergic agents
as a few of the aporphine derivatives of apomorphine have been used as potential therapeutics
for Parkinson’s disease, Schizophrenia among other psychotic disorders.6
1.1.6 (+)-Boldine – History and Pharmacological Profile

Fig. 27: Structure of (+)-boldine, 1
(+)-Boldine

1

(1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-

diol) (Fig. 27) has been isolated from the barks and leaves of the Boldo tree, Peumus boldus
(Monimiaceae) which is indigenous to humid ecosystems of the Mediterranean climactic region
of Central and South Chile.51 Boldo leaves contain between .4 to .5% of at least 17 different
alkaloids belonging to the large benzylisoquinoline-derived family. (+)-Boldine is the major
alkaloid, which accounts for 12-19% of the total alkaloid content. Boldo leaves contain tannins,
essential oils like ascaridole, cineole and flavonoids like catechin. (+)-Boldine is also present as
a minor constituent in a number of other species of the Monimiaceae, Magnoliaceae and
Lauraceae. Interestingly, (+)-boldine content in the leaves of Boldo varies on a seasonal basis
with maximum amounts present during summer.52
Boldo leaves have been used by South American natives against diseases of the liver and
treatment of gallstones.53 The plant is still used as homeopathic medicine for digestive disorders
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as laxatives, diuretics and problems associated with rheumatism among many other ailments.54
(+)-Boldine has been characterized as an antioxidant which protects the cells in different systems
from the scavenging activity of free-radical induced peroxidation or enzyme in activation.52 (+)Boldine exerts anti-inflammatory, anti-pyretic, anti-diabetic, anti-tumor promoting properties.
(+)-Boldine has neuroleptic-like, anticonvulsant and antinociceptive actions. (+)-Boldine could
also boost the immune system as it was found that it was a poor macrophage peroxide liberator
in rats. In addition to a host of pharmacological properties, (+)-Boldine also exerts its effects on
the smooth muscle as a relaxer.52 (+)-Boldine is a slightly selective α-adrenergic antagonist and
non-selectively binding antagonist of D1 and D2 receptors.55, 6
(+)-Boldine has a plasma half-life of only 30 minutes and it may be due to (+)-boldine’s
rapid glucuronidation in the liver. The presence of phenolic groups on (+)-boldine is associated
with low metabolic stability. (+)-Boldine’s short systemic half-life is very disadvantageous in
terms of its potential clinical usefulness. Additionally, it was indicated in studies that (+)-boldine
has low toxicity.52 Research clearly indicates that (+)-boldine has clinically useful properties and
so it is essential to find more stable analogues of (+)-boldine which retains its activity and these
molecules could be useful for therapeutic purposes.
1.1.7 SAR studies on (+)-boldine
(+)-Boldine exhibits a wide range of pharmacological properties which makes it
imperative to conduct SAR studies on (+)-boldine in a variety of assay systems. Only a few
reports have been done on the SAR of (+)-boldine at CNS receptors. These SAR studies on (+)boldine are discussed as they highlight the importance of structural changes on (+)-boldine and
consequently its function.
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Most of the bioactive aporphines like apomorphine and its congeners have (R) antagonist
stereochemistry at the 6α carbon, however, (+)-Boldine has (S) stereochemistry and it’s an
antagonist for the CNS receptors. The substitution patterns on (+)-boldine differs to a great
extent to (R)-apomorphine and derivatives which are DA agonists. Substitution patterns at 1, 2, 9
and 10 Carbon positions on (+)-boldine scaffold are responsible for the DA antagonist
properties.17
In order to increase the metabolic stability and retain/enhance biological activity of (+)boldine, substituents were added to the readily available (+)-boldine scaffold. To that extent, (+)boldine was brominated, chlorinated and iodinated at C-3 position. (Fig. 28) Radioligand binding
studies of the halogenated analogues showed that halogenation at C-3 increased affinity to D1 but
not D2 receptors. From this study, 3-iodoboldine was found to be the most potent derivative with
a low nanomolar IC50 (2 nM). (Fig. 28) In the case of 3-iodoboldine, it lost its activity
completely at the α1 adrenergic receptors, while retaining its activity at D1/D2 receptors. This was
in contrast with the results of other halogenated derivatives, as they displayed both α1 adrenergic
and D1/D2 affinity.56

Fig. 28: Halogenated C3 boldine analogues
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Another study which probed the SAR of (+)-boldine found that compared to (+)-boldine,
bromine or chlorine substitution at C3 positions increases the α1A adrenoreceptors subtype
selectivity and also decreases the affinity of benzothiazepine site at the calcium channel in Rat
cerebral cortex. Halogenation at C8 position did not significantly improve the activity with
respect to 3-bromoboldine. (Fig. 29) Nitroso substitution (Fig. 30) at C3 position resulted in the
loss of affinity and selectivity for the α1A adrenoreceptors subtypes.55 8-NH2-boldine’s (Fig. 31)
affinity was significantly decreased compared to (+)-boldine at α1D adrenoreceptors. These
results suggest that an amino group at C8 hinders molecules from binding to α1D adrenoreceptors
active site.57

Fig. 29: Halogenated C8 boldine analogues

Fig. 30: Nitroso substituted boldine analogue
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Fig. 31: Substituted C8 amine boldine analogue
SAR on (+)-boldine reveals that the phenol groups bonded to the aporphine ring system
and the basic benzylic amine contribute heavily to the biological activity of aporphines and
boldine. Martinez et. al tested (+)-boldine against several other aporphines and it was discovered
that (+)-boldine displayed much pronounced activity possibly owing to the presence of free
hydroxyl group on C-2 of the isoquinoline ring. The free hydroxyl group on C2 was also found
to increase the affinity to D1 over D2, α1A and α1B adrenoreceptors subtypes in rats.55
Milian et. al. semi-synthesized halogenated phenanthrene alkaloids using (+)-boldine as the
starting material. The SAR on (+)-boldine showed that the presence of the free phenolic groups
was essential for the antioxidant activity. The phenanthrene alkaloids without the phenolic
groups (Fig. 32) showed less potency than the alkaloids with the aporphine or the phenanthrene
skeleton. Additionally, compounds with phenols in the phenanthrene skeleton were found to be
more active compounds than the respective alkaloids with the aporphine skeleton. Absence of
phenols in non-phenolic aporphines (Fig. 33) was found to be detrimental for stability as nonphenolic aporphines could be easily oxidized to dehydro- and oxo-aporphines.58
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Fig. 32: C2, C9 substituted phenanthrene analogue

Fig. 33: C2, C9 substituted boldine with preserved aporphine skeleton
Thomet et. al. attached diphenylphosphinyl group at C3 position of (+)-boldine. (Fig. 34)
In screening studies, it was found that with the introduction of phosphinyl group, the
cytotoxicity, lipophilicity and intercalating behavior of (+)-boldine increased substantially. As a
result of this, the diphenylphosphine derivative exhibited significant cytotoxic activity against
two breast cancer lines (MDA-MB-231, MCF-7). 59

Fig. 34: C3 Diphenylphosphinyl substituted boldine derivative
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1.1.8 Objective of Study
(+)-Boldine is readily available commercially and has a chiral center at 6a. The total
synthesis of alkylated derivatives of (+)-boldine at C2 and C9 requires several steps and often
entails laborious purification. Semisynthetic studies on the readily available (+)-boldine scaffold
for the SAR studies at CNS receptors offers considerable advantages as compared to total
synthesis, with respect to yields and synthetic efficiency. Only a few reports have been done on
the SAR studies of (+)-boldine at CNS Receptors. The primary objective of this study is to
evaluate the potential of (+)-boldine derivatives as ligands for serotonin receptors: 5-HT1A, 5HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7. Secondary aim was to evaluate the extent to
which structural changes on (+)-boldine are tolerated for affinity across the 5-HT (Serotonin)
receptors.

As mentioned before 5-HT receptors are implicated in several neuropsychiatric

maladies including schizophrenia, depression, anxiety, insomnia and stimulant addiction.
Systemic studies on the benzylation at C2, C9 positions of (+)-boldine have not been
reported. Study on the SAR of C2, C9 benzylated analogues could potentially lead to novel
ligands that are valuable for understanding receptor−ligand interactions at the CNS that control
receptor affinity, activity and selectivity.
1.1.9 Rationale for synthesis of analogs at C2 and C9 position in (+)-boldine
The central hypothesis of the project was that (+)-boldine can be structurally modified to
give more potent antagonists at various 5-HT receptor subtypes: 5-HT1A, 5-HT1D, 5-HT2A, 5HT2B, 5-HT2C, 5-HT6 and 5-HT7. In order to test this hypothesis, compounds based on the (+)boldine skeleton were semi-synthesized and screened in 5-HT receptor subtype assays for
affinity and antagonist activity.
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Systemic studies on the benzylation at C2, C9 positions of (+)-boldine have not been
reported.

The information we obtain from the study might allow us to understand specific

structural features of (+)-boldine that are necessary for its activity at the 5-HT receptors and
provide more insights into the receptors that are involved in 5-HT agonism/antagonism. Minor
modification to the (+)-boldine skeleton will result in better understanding of the pharmacophore
part of (+)-boldine and could potentially result in identification of novel CNS receptors ligands
which could be used for further studies of receptors and also aid in development of
therapeutics.17
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Chapter 2

2.1 Results and Discussion:
2.1.1 Synthesis of C2 and C9 analogues from (+)-boldine
It was proposed that (+)-boldine could be functionalized to obtain a library of compounds
using Williamson ether synthesis. However, it was found that the reaction of (+)-boldine under
typical Williamson ether synthesis lead to the quarternization of the tertiary Nitrogen and
subsequent cleavage of ring B to afford phenanthrene nucleus. (Scheme 1). The basic nature of
the amine group was found to be problematic and it was deemed necessary to convert the amine
group to a less basic functional group. To this purpose, the amine functionality was converted to
N-carbamate moiety. During this reaction, it was discovered that Ring B of (+)-boldine opens up
to give phenanthrene alkaloid nucleus similar to the products of Williamson ether synthesis. The
Cl- ion generated during the reaction was found to be problematic as it alone was able to convert
(+)-boldine to its phenanthrene variety. Numerous unsuccessful attempts were made to sequester
the chlorine ion from extracting acidic proton from ring C.
Scheme 1: Quarternization of boldine in typical Williamson ether conditions
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Table 2: Typical conditions used for Williamson ether synthesis (Yield = % dibenzylated boldine)
Entry

Benzylbromide Base(K2CO3/LiCo3) Solvent Temperature(oC) Yield

1

1 eq.

1 eq.

Acetone

25

0

2

1.4

1.4

Acetone

25

0

3

1.8

1.8

Acetone

25

0

4

2

2

Acetone

25

0

5

2.2

2.2

Acetone

25

0

6

1

1

Acetone

25

0

7

1.4

1.4

Acetone

25

0

8

1.8

1.8

Acetone

25

0

9

2

2

Acetone

25

0

10

2.2

2.2

Acetone

25

0

11

1

1

DCM

25

0

12

2.2

2.2

DCM

25

0

13

2

2

DCM

70

0

14

2

2

DMF

25

0
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Scheme 2: Alternate route for synthesis of dibenzylated boldine analogues

Table 3: Typical conditions used for amines’ N-carbamate protection (Yield = % dibenzylated boldine)

Entry

Ethyl Carbamate

Base (K2CO3/LiCo3)

Solvent

Temperature(oC)

Yield

1

1 eq.

1 eq.

DCM

0

0

2

1.4

1.4

DCM

0

0

3

1.8

1.8

DCM

0

0

4

2

2

DCM

0

0

5

2.2

2.2

DCM

0

0

6

1

1

Acetone

0

0

7

1.4

1.4

Acetone

0

0

8

1.8

1.8

Acetone

0

0

9

2

2

Acetone

0

0

10

2.2

2.2

Acetone

0

0

11

1

1

DMF

0

0

12

2.2

2.2

DMF

0

0

13

2

2

DCM

70

0

14

2

0

DCM

0

0
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In order to avoid N-alkylation during phenolic alkylation, Mitsunobu reaction was tested as
an alternative method. Phenolic alkylation on aporphines have been done only once, so
exploration of phenolic alkylation is essential for functionalizing phenolic groups on aporphines
like (+)-boldine.42 The route to synthesize (+)-boldine analogues is outlined in Fig. 35. (+)Boldine was subjected to Mitsunobu alkylation to afford a mixture of mono and dialkylated (+)boldine along with complex mixture of the reagents and minute amounts of starting material (+)boldine. The complex mixture was subjected to column chromatography in order to separate the
dialkylated benzyl ethers from the rest of the mixture.

The (+)-boldine was reacted with

Diisopropyl azodicarboxylate (DIAD), appropriate benzyl alcohol and polymer bound
Triphenylphosphine (TPP/PPh3) and the following compounds 2-13 (Table 4) were afforded.
Fortunately, (+)-boldine ethers are separable chromatographically, even though the separation is
somewhat tedious owing to the similarities in Rf.
It was found experimentally that 4 equivalents of the reagents were necessary to afford
maximum yield of dialkylated benzyl ethers of (+)-boldine at C2, C9 positions. During
purification, an acidic impurity was degrading the compounds so column chromatography was
performed in basic alumina to separate the impurity. Additionally, it was very difficult to remove
from PPh3 from the dialkylated compounds as they appeared almost at the same Rf. A solvent
system could not be devised to separate PPh3 from the products. To that extent, polymer bound
PPh3 was used to filter most of the PPh3 from the reaction mixture. Subsequently, column
chromatography in basic alumina and preparatory column in silica was performed to afford pure
compounds 2-13 (Table 4) in moderate yields.
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Fig. 35: Reaction scheme for Synthesis of C2 and C9 (+)-boldine analogues
Table 4: List of Benzyl alcohols used and the compounds made (N/A Not Applicable)

Compound
Boldine (1)
2

Benzyl Alcohol
N/A
4-Bromobenzyl alcohol

R
N/A
3-Bromo

3

4-Methoxybenzyl alcohol

4-Methoxy

4

2-Methoxybenzyl alcohol

2-Methoxy

5

3-Methoxybenzyl alcohol

3-Methoxy

6

4-(Trifluoromethyl)benzyl alcohol

4-(Trifluoromethyl)

7

4-Fluorobenzyl alcohol

4-Fluoro

8

2-Fluorobenzyl alcohol

2-Fluoro

9

3-Fluorobenzyl alcohol

3-Fluoro

10

4-Benzyloxybenzyl alcohol

4-Benzyloxy

11

4-Chlorobenzyl alcohol

4-Chloro

12

4-Methylbenzyl alcohol

4-Methyl

13

4-Iodobenzyl alcohol

4-Iodo
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2.1.2 Reaction Mechanism – Mitsunobu reaction
The substitution of primary or secondary alcohols with nucleophiles mediated by a redox
combination of triarylphosphine and Dialkyl azocarbooxylate is popularly known as Mitsunobu
reaction. Mitsunobu reaction was discovered in 1967 and has been widely used in synthetic
organic chemistry. The Mitsunobu reaction is extensively used to prepare alkyl-aryl ethers under
mild conditions. Apart from ethers, a wide range of compounds which includes esters, amines,
azides, cyanides, thiocyanides, thioesters and thioethers can be synthesized using the Mitsunobu
reaction. Common reagents include DEAD, DIAD, PPh3 among others. The substrates of
Mitsunobu reactions are usually primary or secondary alcohols. The nucleophile is usually an
acidic compound with an –OH, -SH or an –NH group with pKa below 11, however, there have
been cases where nucleophiles with pKa of 15 were also tolerated. Some of the common
nucleophiles used in Mitsunobu reaction are phenols, carboxylic acids among a host of other
acidic compounds. Common solvents for Mitsunobu reaction include THF, toluene, benzene,
DMF, diethyl ether, acetonitrile, dichloromethane and 1,4-dioxane. Preferred P(III) component
used is PPh3 which is quite cheap and readily available commercially. Mitsunobu reaction
produces triphenylphosphine oxide as a byproduct, and the unreacted PPh3 is not water soluble,
and very often these byproducts have to be separated from the desired products through column
chromatography. This is one major disadvantage of Mitsunobu reaction.62
Even though Mitsunobu reaction has been used for a long time, its mechanistic details
particularly at the intermediate stages are still subject of debate and rigorous studies. The order
of the steps greatly varies on the order the reagents are added.61 Studies reveal that in the
beginning of the reaction, TPP forms an adduct with DIAD which leads to the formation DIADPPh3 complex (Fig. 36). Adduct formation step is the fastest step in Mitsunobu reaction. The
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DIAD-PPh3 adduct subsequently, deprotonates/activates the phenol (+)-boldine to form the
oxyphosphonium intermediate in step 3. The DIAD-PPh3 can react with the alcohol instead of
the phenol depending on the order of addition. Subsequently, appropriate benzylic alcohol
attacks the DIAD-PPh3 complex to give the PPh3 and protonated DIAD as degradation products.
If the reacting secondary alcohol in step 5 is chiral, it will lead to inversion products as the
reaction occurs in an SN2 manner. Finally, the boldo-phenoxide attacks the methylene attached
to the aromatic ring to give the (+)-boldine ether. The free phenol on (+)-boldine goes through
the same steps as indicated below (Fig. 36) to finally give the dialkylated (+)-boldine ether.63,64

Fig. 36: Current understanding of Mitsunobu reaction mechanism
2.1.3 Biological Results - Activity at CNS Receptors
(+)-Boldine analogues 2-13 were screened at a number of CNS receptors, ion channel and
transporter sites. This screening was conducted by the Psychoactive Drug Screening Program
(PDSP), at the NIH. (+)-Boldine was first screened at various receptor sites in primary
radioligand binding assays that measure percent inhibition. If less than 50% inhibition was
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obtained at a particular receptor in the primary assay, the compound was considered inactive and
was not used for secondary assays. Secondary assays were only performed at those receptors
where inhibition was greater than 50%. The secondary assays are used to calculate the binding
affinity (Ki) values at serotonin receptor subtypes: 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5HT6 and 5-HT7.60
The data from the primary screen (Table 5) suggests that the percent inhibition by the parent
compound (+)-boldine, 1 was much greater than its benzylated analogues (2-13) at the 5-HT1A,
5-HT1D, 5-HT6, 5-HT7 receptor subtypes. However, the percent inhibition at the 5-HT2A and 5HT2B and 5-HT2C receptors sites is higher for the benzylated analogues (2-13) than the parent
molecule (+)-boldine, 1. The only exceptions were compounds 4 and 10 at the 5-HT2B receptor
subtype which had lower percent inhibition than (+)-boldine, 1. The primary screen data
suggested that compounds 2, 9 were considered inactive at the 5-HT6 and 5-HT2B receptor
subtypes. Interestingly, compound 10’s inhibition was insignificant for all the receptors except
for 5-HT2A and 5-HT2C receptor subtypes.
Table 5: Percent Inhibition of benzylated analogues 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C,
5-HT6 and 5-HT7 receptors (NA: Not Applicable and N/A: Not Available)
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% Inhibition
R

Compound 5-HT1A 5-HT1D 5-HT2A

5-HT2B

5-HT2C

5-HT6

5-HT7

Boldine

1

87.7

95.8

56.5

70.0

50.9

88.1

93.5

p-Bromo

2

86.7

72.8

79.3

70.8

90.6

19.3

81.3

p-Chloro

11

78.1

69.7

94.1

82

96.2

54.4

87.1

p-Iodo

13

70.1

79

91.2

89.2

95.8

64.1

81

p-Fluoro

7

81.1

80

90.1

87.9

94.1

64.9

93.5

m-Fluoro

9

73.2

55.8

71.8

44.8

83

49.6

76.6

o-Fluoro

8

65

79.3

91.9

84.5

94.2

67.8

N/A

p-Trifluoromethyl

6

78.2

73.1

74.7

86

96.4

67.1

N/A

p-Methyl

12

83.9

81.8

95.3

90.8

96

69.4

N/A

p-Benzyloxy

10

25.7

41.1

70.1

24.9

88.5

7.4

N/A

p-Methoxy

3

72.6

79.6

85.5

65.4

94.8

41.2

N/A

m-Methoxy

5

76.4

82.1

94.1

78.6

97.9

53

NA

o-Methoxy

4

72.3

63.3

80.9

50

93.1

15.6

NA

SAR at 5-HT1A receptors:
The affinity (Table 6) of most of the screened compounds at 5-HT1A is in the moderate
range (200nM to 1000nM). The compound with the highest affinity at 5HT1A was 12, pMethylbenzyl ether with affinity of 289nM. However, the 5-HT1A site had low affinity values for
compounds 4, 8, and 9. It is interesting to note that Compound 10 is inactive at 5HT1A.
Bisbenzylation of (+)-boldine was found to be disruptive at the 5-HT1A receptor, as the
compounds 2-13 lost its affinity with respective to its parent compound (+)-boldine.
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The electronic nature of compounds seems to be important for binding at the 5-HT1A
receptors. This is evident from the loss of affinity from the para->meta->ortho analogues of
fluorobenzyl and methoxybenzyl compounds. Halogens electronegativity seems to play an
important role in the affinity for 5HT1A, as p-Bromobenzyl ether had the highest affinity for
5HT1A and the most electron withdrawing compound p-Trifluoromethyl-benzyl had the lowest
affinity in the series of compounds. However, p-Iodobenzyl ether contained the least
electronegative element Iodine and the pattern of low electronegativity and high affinity does not
hold true. The presence of bulky p-Benzyloxybenzyl group might be hindering compound 10,
from binding the binding pocket of the 5-HT1A active site. This might indirectly imply that the
binding pocket in the active site for 5-HT1A is significantly smaller than the 5-HT1A 5-HT1D 5HT2B and 5-HT6 receptors.
SAR at 5-HT1D receptors:
The 5-HT1D receptors subtype had moderate to low activity for most of the compounds 213. However, compounds 9, 10 were inactive at the 5-HT1D receptors. Compound 7, pFluorobenzyl ether, was the most active analogue in the series with affinity of 257nM. pFluorobenzyl was more active than and p-Iodobenzyl compound in the para series of the
halogens. This suggests for halogens an increase in electronegativity is associated with an
increase in affinity. There seems to be no other distinct affinity pattern for the compounds at 5HT1D receptors. Benzylation of (+)-boldine was found to be disruptive at the 5-HT1D receptor, as
the compounds 2-13 lost its affinity with respective to its parent compound (+)-boldine.
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SAR at 5-HT2A receptors:
The benzylated compounds 2-13 had moderate activity at 5-HT2A receptors. The benzylated
analogues increased (+)-boldine’s affinity at 5-HT2A receptor 3-13 times. Compound 7, pFluorobenzyl ether was the most active analogue with an affinity of 155nM. Compound 3, pMethoxybenzyl ether had the lowest affinity (646 nM) in the series. Interestingly compound 10
which was inactive at most subtypes is moderately active at 5-HT2A. There is no pattern evident
to suggest that the electronics or sterics are play key roles in binding 5-HT2A receptors.
SAR at 5-HT2B receptors
Compounds 6, 10, 12 and 13 were found to be inactive at 5-HT2B receptors. Compounds 4, 5, 7,
8 and 9 had increased affinity to 5-HT2B receptors with respect to (+)-boldine. However, in the
case of 2, 3 and 11 the binding affinity decreased compared to (+)-boldine. o-Methoxybenzyl, 4
was the most potent compound with an affinity of 37 nM. There seems to be no distinct pattern
in benzylation to suggest that sterics or electronics play key roles in affecting binding affinity to
5-HT2B receptors.
SAR at 5-HT2C receptors:
The benzylated compounds 2-13 had high to moderate activity at 5-HT2C receptors. The
benzylated analogues increased (+)-boldine’s affinity at 5-HT2C receptor 6-46 times. pMethoxybenzyl 3 was the least active compound with an affinity of 329nM. Compound 8, oFluorobenzyl ether was the most active analogue with an affinity of 45nM. Compound 10, which
was found to be inactive at most of the serotonin receptors was found to be moderately active at
5-HT2C receptor
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SAR at 5-HT6 receptors:
The 5-HT6 receptor had the least affinity (moderate to low) for the benzylated analogs of the
two receptors subtypes. o-Methoxybenzyl ether was found to be the least disruptive substituent
with an affinity of 453 nM. Benzylation significantly decreased the affinity of (+)-boldine at the
5-HT6 receptor.
Table 6: Affinity (Ki in nM) of benzylated analogues at 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2B, 5HT2C, 5-HT6 and 5-HT7 receptors (NA: Not Applicable and N/A: Not Available)

Ki in nM
R

Compound

5-HT1A

5-HT1D

5-HT2A

5-HT2B

5-HT2C

5-HT6

5-HT7

NA(Boldine)

1

90

10

1960

459

2064

159

12

p-Bromo

2

326

401

630

1366

73

Inactive

273

p-Chloro

11

367

406

226

953

105

Inactive

N/A

p-Iodo

13

610

2274

355

Inactive

108

Inactive

N/A

p-Fluoro

7

679

257

155

350

136

803

N/A

m-Fluoro

9

1088

Inactive

190

204

79

516

N/A

o-Fluorobenzyl

8

1417

584

237

136

45

815

N/A
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p-Trifluoromethyl

6

883

1446

482

Inactive

331

Inactive

N/A

p-Methyl

12

289

540

199

Inactive

67

1087

N/A

p-Benzyloxy

10

Inactive

Inactive

364

Inactive

307

Inactive

N/A

p-Methoxy

3

549

1613

646

630

329

2761

484

m-Methoxy

5

700

557

261

78

179

589

230

o-Methoxy

4

1213

578

453

37

64

453

557

2.1.4 Conclusions
Mitsunobu reactions were implemented that enabled for rapid, moderate yielding semisynthesis of benzyl-alkylated ether analogues at the C2, C9 position of (+)-boldine. The synthetic
procedure can be used to synthesize numerous alkylated ether analogues from various naturally
occurring alkaloids as well as many synthetic compounds.
From the study it is evident that benzylation increases the affinity of the compounds 2-13
at the 5-HT2A and 5-HT2C receptors. This supports our original hypothesis that benzylations at
C2, C9 positions of (+)-boldine can be used to develop more potent analogs at two serotonin
receptors: 5-HT2A and 5-HT2C.
The phenolic groups present in (+)-boldine makes it difficult for drug development as the
phenolic groups are glycosylated and sulfated, which subsequently leads to low bioavailability of
the compound.60 Benzylation of (+)-boldine helps mask the phenol moiety without decreasing
the potency of compounds 2-13 for the 5-HT2A and 5-HT2C receptors. The retention of activity at
5-HT2A and 5-HT2C receptors should engender more metabolically stable compounds in-vivo as
benzylated compounds protect the labile phenolic groups seem to be essential for improving the
pharmacokinetic profile of molecules like (+)-boldine.
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The most potent benzylated compounds were o-Methoxybenzyl ether, 4 with an affinity of
37nM and o-Fluorobenzyl ether, 8 with an affinity of 45nM at the 5-HT2B and 5-HT2C receptors
respectively. However, considering selectivity the most interesting ligand is p-Benzyloxybenzyl,
10, which is selective only for the 5-HT2A and 5-HT2C receptors. It is interesting to note that oFluorobenzyl ether, 8 had a 46-fold increase in affinity at the 5-HT2A receptor compared to the
parent compound (+)-boldine, 1.
In the future, additional studies will be done to further query how the structural changes at
C2, C9 position of (+)-boldine affects antagonism at the 5-HT receptor subtypes: 5-HT1A, 5HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7
The study has positively impacted the field of (+)-boldine research by identifying potent
ligands based on the (+)-boldine scaffold. The synthetic and biological work described herein
sets the stage for future optimization studies.
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2.1.6 Appendices:

Supporting Information:
General Information:Commercial reagents from Santacruz chemicals, Acros organics, Sigma Aldrich and Maybridge
were purchased at the highest commercial purity and used without further purification unless
otherwise stated. Analytical TLC was performed on 254µm Whatman silica gel (Aluminum
backing, UV 254 nm) plates using UV light and Cerium Molybdate in Sulfuric acid as
visualizing agents. Column chromatography was carried out using Aluminum Oxide, basic
Brockmann 1, 500-200 µm, 60A.
1

H NMR, 13C spectra were recorded on Bruker Avance III 400MHz or Varian INOVA 500MHz

and

19

F spectra were recorded on Bruker Avance III 400MHz. The samples were dissolved in

CDCl3, unless otherwise noted. The following abbreviations are used to explain the
multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of
triplets; dq, doublet of quartets; ddd, doublet of doublet of doublets, m, multiplets. Highresolution mass spectra were obtained from the Mass Spectroscopy Facility at the Hunter
College, The City University of New York.
General Procedure for benzylation at C2, C9 positions on (+)-boldine scaffold
(+)-Boldine (1eq .200g), polymer bound TPP (4eq), benzylic alcohol (4eq) were added to a 2
neck RBF under argon. Anhydrous THF was added and the mixture was then cooled to 0o C for
15 min. DIAD (4eq) was added dropwise slowly via a syringe. The reaction mixture was kept
under ice for an additional hour and then at rt for 8 h. The progress of the reaction was monitored
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via TLC in 5%MeOH/95%DCM solvent system. The solvent was evaporated in vacuo and the
mixture was dissolved in DCM and filtered via Celite. Water (20mL) was added and the organic
layer was then extracted with DCM (3x35mL). Saturated NaCl was added to aid in better
separation. The combined organic layers were dried under Na2SO4. The solvent was removed
under reduced pressure. The residue was purified by flash chromatography in basic alumina
(80%EtOAc/20%Hexane followed by 98%EtOAc/2%MeOH). Subsequently, preparatory TLC
was performed to further purify the compounds 2-13 (2-5%MeOH/DCM). The compounds were
kept in freezer (-20oC) as it was found that moisture degrades the residues.

2,9-bis((4-bromobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (2)
Yield 51.6%, Appearance: Amber brown
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.52 (dd, J=2.8 ,4.8 Hz, 4H), 7.35 (d, 4H, J = 8 Hz),

6.77 (s, 1H), 6.62 (s, 1H), 5.17-5.04 (m, 4H), 3.91 (s, 3H), 3.69 (s, 3H), 3.22-2.93 (m, 4H), 2.672.57 (m, 6H).
C NMR (125 MHz, CDCl3): δ 150.9 (C), 148.1 (C), 147.1 (C), 144.8 (C), 136.3 (C), 136.2 (C),

13

131.7 (C), 129.3 (C), 129.0 (C), 129.0 (C), 127.1 (C), 125.3 (C), 121.8 (C), 121.8 (C), 113.4 (C),
112.5 (C), 112.3 (C), 70.3 (CH2), 70.1 (CH2), 62.5 (C), 60.3 (C), 56.1 (CH2), 53.2 (CH2), 44.0
(C), 34.4 (CH2), 29.2 (C).
HRMS (EI) m/z calcd for [M]+: 664.069 found: 664.0693 Melting point: 74.6-76.6oC

62

1,10-dimethoxy-2,9-bis((4-methoxybenzyl)oxy)-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (3)
Yield 56.2%, Appearance: Brownish white
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.40 (dd, J=3.6, 4.8 Hz, 4H), 6.92 (d, 4H, J = 8.4

Hz), 6.82 (s, 1H), 6.65 (s, 1H), 5.15-5.02 (m, 4H), 3.89 (s, 3H), 3.82 (s, 3H), 3.82 (s, 3H), 3.68
(s, 3H), 3.15-2.93(m, 4H), 2.66-2.47 (m, 6H).
C NMR (125 MHz, CDCl3): δ 159.4 (C), 151.2 (C), 148.1 (C), 147.4 (C), 144.9 (C), 129.3 (C),

13

129.2 (C), 129.1 (C), 127.1 (C), 125.0 (C), 114.0 (C), 114.0 (C), 113.3 (C), 112.4 (C), 112.3 (C),
70.7 (CH2), 70.6 (CH2), 62.6 (CH2), 60.2 (C), 56.2 (CH2), 56.1 (CH2), 55.3 (C), 53.3 (CH2), 44.0
(C), 34.5 (C), 30.9 (C), 29.2 (C).
HRMS (EI) m/z calcd for [M]+: 568.2698 found: 568.2694 Melting point: 90.2-93.8oC

1,10-dimethoxy-2,9-bis((2-methoxybenzyl)oxy)-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (4)
Yield 40.9%, Appearance: Light brown
1

H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.54 (d, J=7.2 Hz, 2H), 7.32-7.26 (m, 2H), 7.00-6.98

(m, 2H), 6.91 (d, 2H J=8.4 Hz), 6.83 (s, 1H), 6.68 (s, 1H), 5.28-5.12 (m, 4H), 3.92 (s, 3H), 3.88
(s, 3H), 3.87 (s, 3H), 3.72 (s, 3H), 3.16-2.93(m, 4H), 2.67-2.46 (m, 6H).
C NMR (125 MHz, CDCl3): δ 156.6 (C), 151.3 (C), 148.0 (C), 147.5 (C), 144.7 (C), 129.3 (C),

13

128.8 (C), 128.6 (C), 128.4 (C), 128.3 (C), 127.0 (C), 125.6 (C), 125.6 (C), 124.9 (C), 120.7 (C),
120.6 (C), 113.0 (C), 112.3 (C), 112.1 (C), 110.1 (C), 65.8 (C), 65.7 (C), 62.6 (C), 60.2 (C), 56.2
(C), 55.4 (C), 55.3 (C), 53.3 (C), 44.0 (C), 34,5 (C), 29.2 (C).
HRMS (EI) m/z calcd for [M]+: 568.2688 found: 568.2694 Melting point: 57.0-60.5oC
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1,10-dimethoxy-2,9-bis((3-methoxybenzyl)oxy)-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinolone (5)
Yield 37.8%, Appearance: Brown
1

H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.32-7.28 (m, 2H), 7.06-7.04 (m, 4H), 6.87-6.84 (m,

2H), 6.80 (s, 1H), 6.63 (s, 1H), 5.20-5.08 (m, 4H), 3.91 (s, 3H), 3.82 (s, 3H), 3.82 (s, 3H), 3.72
(s, 3H), 3.12-3.11 (m, 1H), 3.03-2.92 (m, 3H), 2.64 (d, 1H, J=2.4Hz), 2.62-2.49 (m, 6H).
C NMR (125 MHz, CDCl3): δ 159.9 (C), 159.9 (C), 151.1 (C), 148.1 (C), 147.3 (C), 144.8 (C),

13

138.9 (C), 138.8 (C), 129.6 (C), 129.3 (C), 128.9 (C), 127.8 (C) 127.1 (C), 125.2 (C), 119.5 (C),
113.4 (C), 113.3 (C), 113.3 (C), 112.8 (C), 112.7 (C), 112.4 (C), 112.3 (C), 70.9 (CH2), 70.6
(CH2), 62.5 (CH2), 60.3 (C), 56.1 (CH2), 55.3 (CH2), 55.2 (C)¸ 53.3 (C), 44.0 (C), 34.5 (CH2),
29.2 (C).
HRMS (EI) m/z calcd for [M]+: 568.2701 found: 568.2694 Melting point: 52.2-54.1oC

1,10-dimethoxy-6-methyl-2,9-bis((4-(trifluoromethyl)benzyl)oxy)-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (6)
Yield 49.2%, Appearance: Yellow brown
1

H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.67-7.64 (m, 4H), 7.60 (d, 4H, J = 8 Hz), 6.79 (s,

1H), 6.63 (s, 1H), 5.29-5.15 (m, 4H), 3.93 (s, 3H), 3.71 (s, 3H), 3.16-2.93 (m, 4H), 2.66-2.46 (m,
6H).
C NMR (125 MHz, CDCl3): δ 150.9 (C), 148.1 (C), 147.0 (C), 144.9 (C), 141.3 (C), 141.3 (C),

13

130.5 (C), 130.5 (C), 130.2 (C), 130.2 (C), 130.0 (C), 129.9 (C), 129.7 (C), 129.7 (C), 129.4 (C),
129.1 (C), 128.3 (C), 127.3 (C), 127.2 (C), 125.6 (C), 125.6 (C), 125.6 (C), 125.5 (C), 125.5 (C),
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113.5 (C), 112.5 (C), 112.4 (C), 77.3 (C), 77.0 (C), 76.8 (C), 70.2 (C), 70.0 (C), 62.5 (C), 60.3
(C), 56.2 (C), 53.2 (C), 44.0 (C), 34.4 (C), 29.2 (C).
19

F NMR (470MHz) δ 62.51, 62.52

HRMS (EI) m/z calcd for [M]+: 644.2239 found: 644.223 Melting point: 72.0-75.1oC

9-((3-fluorobenzyl)oxy)-2-((4-fluorobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7tetrahydro-4H-dibenzo[de,g]quinolone (7)
Yield 50.3%, Appearance: Yellow brown
1

H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.47-7.43 (m, 4H), 7.10-7.05 (m, 4H), 7.09-7.05 (m,

4H), 6.80 (s, 1H), 6.64 (s, 1H), 5.17-5.04 (m, 4H), 3.90 (s, 3H), 3.69 (s, 3H), 3.15-2.93 (m, 4H),
2.66-2.46 (m, 6H).
C NMR (125 MHz, CDCl3): δ 163.5 (C), 161.5 (C), 161.5 (C), 151.0 (C), 148.2 (C), 147.2 (C),

13

144.9 (C), 132.9 (C), 132.9 (C), 129.3 (C), 129.3 (C), 129.2 (C), 129.0 (C), 128.0 (C), 127.1 (C),
125.3, 115.6 (C), 115.4 (C), 113.4 (C), 112.5 (C), 112.3 (C), 70.4 (C), 70.2 (C), 62.5 (C), 60.3
(C), 56.1 (C), 53.3 (C), 44.0 (C), 34.5 (C), 29.3 (C).
19

F NMR (470MHz) δ114.35, 114.45

HRMS (EI) m/z calcd for [M]+: 544.2301 found: 544.2294 Melting point: 59.3-63.0oC
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2,9-bis((2-fluorobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (8)
Yield 45.1%, Appearance: Amber brown
1

H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.61-7.55 (m, 2H), 7.32-7.27 (m, 2H), 7.19-7.15

(m,2H), 7.12-7.06 (m, 2H), 6.85 (s, 1H), 6.69 (s, 1H) 5.26-5.15 (m, 4H), 3.90 (s, 3H), 3.70 (s,
3H), 3.14-2.95 (m, 4H), 2.680-2.50 (m, 6H).
C NMR (125 MHz, CDCl3): δ 161.3 (C), 159.5 (C), 159.4 (C), 150.9 (C), 148.2 (C), 147.1 (C),

13

144.8 (C),129.8 (C), 129.7 (C), 129.7 (C), 129.7 (C), 129.6 (C), 129.6 (C), 129.5 (C), 129.4 (C),
129.0 (C), 128.0 (C), 127.1 (C), 125.3 (C), 124.4 (C), 124.4 (C), 124.3 (C), 124.3 (C), 124.3 (C),
124.3 (C), 115.4 (C), 115.3 (C), 115.2 (C), 115.1 (C), 113.3 (C), 112.4 (C), 112.3 (C), 64.6 (C),
64.6 (C), 64.6 (C), 64.5 (C), 62.5 (C), 60.3 (C), 56.2 (C), 53.3 (C), 44.0 (C), 34.4 (C), 29.2 (C).
19

F NMR (470MHz) δ118.62, 118.78

HRMS (EI) m/z calcd for [M]+: 544.2298 found: 544.2294 Melting point: 60.6-63.9oC

2,9-bis((3-fluorobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinolone (9)
Yield 25.7%, Appearance: brown
1

H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.38-7.33 (m, 2H), 7.25-7.20 (m, 4H) 7.04-6.98 (m,

2H), 6.78 (s, 1H), 6.62 (s, 1H), 5.22-5.09 (m, 4H), 3.92 (s, 3H), 3.71 (s, 3H), 3.17-2.93 (m, 4H),
2.66-2.48 (s, 6H).
C NMR (125 MHz, CDCl3): δ 164.0 (C), 162.1 (C), 162.0 (C), 150.9 (C), 148.2 (C), 147.1 (C),

13

144.8 (C), 139.9 (C), 139.8 (C), 139.8 (C), 139.7 (C), 130.2 (C), 130.1 (C), 127.2 (C), 125.3 (C),
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122.6 (C), 122.6 (C), 122.6 (C), 114.9 (C), 114.8 (C), 114.8 (C), 114.7 (C), 114.7 (C), 114.7 (C),
114.2 (C), 114.0 (C), 113.4 (C), 112.4 (C), 112.3 (C), 70.2 (C), 70.2 (C), 70.0 (C), 70.0 (C), 62.5
(C), 60.3 (C), 56.2 (C), 56.1 (C), 53.2 (C), 44.0 (C), 34.4 (C), 29.7 (C), 29.1 (C), 21.8 (C), 21.7
(C), 21.7 (C).
19

F NMR (470MHz) δ112.82, 112.90

HRMS (EI) m/z calcd for [M]+: 664.069 found: 664.0693 Melting point: 51.7-54.3oC

2,9-bis((4-(benzyloxy)benzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline (10)
Yield 54.2%, Appearance: Yellow brown
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.44-7.30 (m, 14H), 6.99 (d, 4H, J=8Hz), 6.81 (s,

1H), 6.65 (s, 1H), 5.14-5.01 (m, 4H), 3.88 (s, 3H), 3.67 (s, 3H), 3.13-2.93 (m, 4H), 2.66-2.48 (s,
6H).
C NMR (125 MHz, CDCl3): δ 158.6 (C), 151.2 (C), 148.1 (C), 147.4 (C), 144.9 (C), 137.0 (C),

13

136.9 (C), 129.6 (C), 129.3 (C), 129.2 (C), 129.1 (C), 128.8 (C), 128.6 (C), 128.0 (C), 128.0 (C),
127.7 (C),127.5 (C), 127.1 (C), 125.1 (C), 114.9 (C), 114.9 (C), 113.30 (C), 112.4 (C), 112.3 (C),
70.7 (C), 70.5 (C), 70.1 (C), 70.0 (C), 62.6 (C), 60.2 (C), 56.1 (C), 53.3 (C), 44.0 (C), 34.5 (C),
29.3 (C).
HRMS (EI) m/z calcd for [M]+: 720.3315 found: 720.332 Melting point: 62.7-64.8oC
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2,9-bis((4-chlorobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinolone (11)
Yield 53.5%, Appearance: Yellow brown
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.42 (m, 4H), 7.38-7.35 (m, 4H), 6.78 (s, 1H), 6.62

(s, 1H), 5.16-5.08 (m, 4H), 3.91 (s, 3H), 3.69 (s, 3H), 3.15-2.92 (m, 4H), 2.65-2.47 (m, 6H).
C NMR (125 MHz, CDCl3): δ 150.9 (C), 148.2 (C), 147.1 (C), 144.8 (C), 135.7 (C), 135.7 (C),

13

133.7 (C), 133.7 (C), 129.3 (C), 129.0 (C), 128.8 (C), 128.7 (C), 128.7 (C), 127.1 (C), 125.3 (C),
113.4 (C), 112.5 (C), 112.3 (C), 70.3 (C), 70.1 (C), 62.5 (C), 60.3 (C), 56.1 (C), 53.4 (C), 44.0
(C), 34.5 (C), 29.2 (C).
HRMS (EI) m/z calcd for [M]+: 576.1703 found: 576.1703 Melting point: 69.1-72.5oC

1,10-dimethoxy-6-methyl-2,9-bis((4-methylbenzyl)oxy)-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinolone (12)
Yield 49%, Appearance: Brown
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.37-7.35 (m, 4H), 7.19 (d, 4H, J = 7.6 Hz), 6.80 (s,

1H), 6.65 (s, 1H), 5.18-5.05 (m, 4H), 3.906 (s, 3H), 3.69 (s, 3H), 3.30-2.94 (m, 4H), 2.67-2.36
(m, 6H).
C NMR (125 MHz, CDCl3): δ 151.2 (C), 148.1 (C), 147.4 (C), 144.8 (C), 137.6 (C), 137.5 (C),

13

134.2 (C), 134.2 (C), 129.2 (C), 129.2 (C), 128.8 (C), 127.6 (C), 127.5 (C), 127.4 (C), 127.1 (C),
125.0 (C), 113.2 (C), 112.3 (C), 112.3 (C), 70.8 (C), 70.7 (C), 62.5 (C), 60.2 (C), 56.1 (C), 53.3
(C), 44.0 (C), 34.5 (C), 29.2 (C), 21.2 (C).
HRMS (EI) m/z calcd for [M]+: 536.2799 found: 536.2795 Melting point: 64.7-67.9oC
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2,9-bis((4-iodobenzyl)oxy)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinolone (13)
Yield 48.5%, Appearance: Yellow brown
1

H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.73-7.70 (m, 4H), 7.22 (d, 4H, J = 8 Hz), 6.76 (s,

1H), 6.61 (s, 1H), 5.16-5.03 (m, 4H), 3.90 (s, 3H), 3.68 (s, 3H), 3.15-2.92 (m, 4H), 2.64-2.53 (m,
6H).
C NMR (125 MHz, CDCl3): δ 150.9 (C), 148.1 (C), 147.1 (C), 144.8 (C), 137.7 (C), 136.9 (C),

13

136.9 (C), 129.2 (C), 129.1 (C), 128.9 (C), 127.1 (C), 125.3 (C), 113.4 (C), 112.2 (C), 112.3 (C),
93.4 (C), 93.3 (C), 70.3 (C), 70.11 (C), 62.5 (C), 60.3 (C), 56.1 (C), 53.2 (C), 44.0 (C), 34.4 (C),
29.2 (C).
HRMS (EI) m/z calcd for [M]+: 760.0417 found: 760.0415 Melting point: 80.9-84.4oC
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